Covered recipient · General Payments record
SRILATA GUNDALA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$2,898.91
105 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,293.07 | 99 |
| Long term medical supply or device loan | $398.80 | 4 |
| Education | $207.04 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SRILATA GUNDALA
NPI 1467646141 · CMS profile ID 67012
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HINSDALE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
105 matching records · $2,898.91 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 105.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.99 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141610443 | CMS |
| Janssen Biotech, Inc. | $27.36 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590917 | CMS |
| AstraZeneca Pharmaceuticals LP | $99.99 | 07/08/2024 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155841520 | CMS |
| AstraZeneca Pharmaceuticals LP | $2.43 | 06/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105284017 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.26 | 06/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105887041 | CMS |
| Janssen Biotech, Inc. | $24.28 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590538 | CMS |
| Gilead Sciences, Inc. | $22.39 | 06/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133800568 | CMS |
| ABBVIE INC. | $26.87 | 06/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103850826 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.99 | 06/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094037405 | CMS |
| PFIZER INC. | $26.85 | 06/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131703466 | CMS |
| Novartis Pharmaceuticals Corporation | $21.91 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086850029 | CMS |
| PFIZER INC. | $18.04 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131349641 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.05 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114061603 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.83 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104650837 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.30 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144958396 | CMS |
| Novartis Pharmaceuticals Corporation | $25.99 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086850031 | CMS |
| Celgene Corporation | $16.61 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101154906 | CMS |
| JAZZ PHARMACEUTICALS INC. | $29.67 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150216578 | CMS |
| Mirati Therapeutics, Inc. | $17.44 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117171838 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.69 | 05/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105454427 | CMS |
| Novartis Pharmaceuticals Corporation | $11.72 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086850027 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.33 | 04/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104442993 | CMS |
| Tempus AI, Inc | $9.27 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150165710 | CMS |
| Lilly USA, LLC | $10.40 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135414517 | CMS |
| Janssen Biotech, Inc. | $27.25 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590498 | CMS |
| ABBVIE INC. | $24.89 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103850824 | CMS |
| Amneal Pharmaceuticals LLC | $27.27 | 04/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139187788 | CMS |
| GENZYME CORPORATION | $28.45 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139955953 | CMS |
| Genentech USA, Inc. | $31.83 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133114853 | CMS |
| Lilly USA, LLC | $107.05 | 04/05/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135429001 | CMS |
| Lilly USA, LLC | $20.24 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135349491 | CMS |
| Pharmacosmos Therapeutics Inc. | $25.72 | 03/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154822169 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.47 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086152357 | CMS |
| PFIZER INC. | $13.59 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131302599 | CMS |
| PFIZER INC. | $26.29 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131295391 | CMS |
| PFIZER INC. | $17.10 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131288367 | CMS |
| Alexion Pharmaceuticals, Inc. | $24.54 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093926504 | CMS |
| Janssen Biotech, Inc. | $19.84 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590738 | CMS |
| ABBVIE INC. | $26.87 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103850822 | CMS |
| Lilly USA, LLC | $15.55 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135414519 | CMS |
| Novartis Pharmaceuticals Corporation | $17.08 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086850025 | CMS |
| Janssen Biotech, Inc. | $22.83 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590505 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.89 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114061601 | CMS |
| Mirati Therapeutics, Inc. | $13.53 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117171835 | CMS |
| Astellas Pharma US Inc | $27.46 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139311598 | CMS |
| Tempus AI, Inc | $65.68 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150165708 | CMS |
| Tempus AI, Inc | $6.04 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150165706 | CMS |
| Janssen Biotech, Inc. | $29.16 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078590796 | CMS |
| Lilly USA, LLC | $15.89 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135398259 | CMS |
| Novartis Pharmaceuticals Corporation | $9.07 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086850023 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,158,956.38 | 214 |
| PY2024 | Principal investigator | $1,000,365.79 | 67 |
| PY2023 | Principal investigator | $106,650.71 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
214 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Aadi Bioscience, Inc. | $64,929.53 | 12/31/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/?TSC2 Genes (PRECISION 1) | No dispute reported | 06/30/2026 | 1255063022 |
| Principal investigator 1 | PFIZER INC. | $35,750.00 | 12/31/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228804925 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,148.00 | 12/19/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190330707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 12/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184279122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 12/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184279124 |
| Principal investigator 1 | PFIZER INC. | $35,750.00 | 12/18/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228804919 |
| Principal investigator 1 | PFIZER INC. | $19,908.70 | 12/17/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228714333 |
| Principal investigator 1 | PFIZER INC. | $356.50 | 12/17/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228714337 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 12/17/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228714411 |
| Principal investigator 1 | PFIZER INC. | $461.25 | 12/17/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228714447 |
| Principal investigator 1 | PFIZER INC. | $2,987.04 | 12/17/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228714451 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 12/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVIC | Fruquintinib | No dispute reported | 06/30/2026 | 1223289876 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVIC | Fruquintinib | No dispute reported | 06/30/2026 | 1223289878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.81 | 12/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $641.56 | 12/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $183.68 | 12/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 12/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274673 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $47,950.00 | 12/10/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185539509 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,929.40 | 12/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185539515 |
| Principal investigator 1 | ABBVIE INC. | $1,015.20 | 12/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202527938 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 12/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202527940 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 12/04/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228714042 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 12/04/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228714413 |
| Principal investigator 1 | PFIZER INC. | $12,247.56 | 12/04/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228714523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,940.28 | 12/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184269289 |
| Principal investigator 1 | ABBVIE INC. | $1,270.98 | 12/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202526396 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,207.20 | 12/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185539505 |
| Principal investigator 1 | PFIZER INC. | $208.00 | 12/02/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228714040 |
| Principal investigator 1 | PFIZER INC. | $82.08 | 12/02/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228714335 |
| Principal investigator 1 | PFIZER INC. | $19,628.80 | 12/02/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228714449 |
| Principal investigator 1 | PFIZER INC. | $768.00 | 12/02/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228714521 |
| Principal investigator 1 | ABBVIE INC. | $8,998.98 | 11/26/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202525520 |
| Principal investigator 1 | ABBVIE INC. | $2,431.56 | 11/26/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202525522 |
| Principal investigator 1 | PFIZER INC. | $10,965.52 | 11/26/2025 | Non-covered Recipient Entity HOPE AND HEALING CLINICAL RESEARCH | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228807072 |
| Principal investigator 1 | PFIZER INC. | $425.00 | 11/26/2025 | Non-covered Recipient Entity HOPE AND HEALING CLINICAL RESEARCH | AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228807077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 11/25/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184264537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,500.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,806.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317493 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,800.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $24,000.00 | 11/24/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317503 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,200.00 | 11/24/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930681 |
| Principal investigator 1 | ABBVIE INC. | $45.00 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202524852 |
| Principal investigator 1 | Genmab U.S., Inc. | $550.00 | 11/20/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184263727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $560.14 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184263729 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.82 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184263731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $360.18 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184263733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $477.48 | 11/20/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184263735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 11/14/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175414396 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 11/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202524157 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,148.00 | 11/12/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342838 |
| Principal investigator 1 | PFIZER INC. | $5,500.00 | 11/07/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228818092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.53 | 11/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184259085 |
| Principal investigator 1 | ABBVIE INC. | $7,000.00 | 11/06/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202523361 |
| Principal investigator 1 | ABBVIE INC. | $7,000.00 | 11/06/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202523363 |
| Principal investigator 1 | ABBVIE INC. | $5,364.90 | 11/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202522111 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,117.20 | 11/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVIC | Fruquintinib | No dispute reported | 06/30/2026 | 1223288055 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,466.80 | 11/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVIC | Fruquintinib | No dispute reported | 06/30/2026 | 1223288083 |
| Principal investigator 1 | ABBVIE INC. | $28.00 | 10/30/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202519769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $333.96 | 10/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,079.66 | 10/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 10/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253724 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.82 | 10/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253726 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 10/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253728 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $587,650.48 | 10/28/2025 | Non-covered Recipient Entity HOPE AND HEALING CARE | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190309836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,511.00 | 10/24/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414329 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 10/24/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414353 |
| Principal investigator 1 | ABBVIE INC. | $80.00 | 10/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202518323 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202518339 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 10/21/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202517609 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,929.40 | 10/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185539503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,914.80 | 10/16/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184250721 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $26,600.00 | 10/14/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190329709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $370.00 | 10/14/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317485 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $945.00 | 10/14/2025 | Non-covered Recipient Entity Hope And Healing Cancer Services Hinsdale Office | DS8201-793 | No dispute reported | 06/30/2026 | 1225317487 |
| Principal investigator 1 | Genmab U.S., Inc. | $716.30 | 10/14/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 10/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175414372 |
| Principal investigator 1 | ABBVIE INC. | $13,146.30 | 10/09/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202515297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,940.28 | 10/09/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184248988 |
| Principal investigator 1 | Genentech, Inc. | $37,000.00 | 10/06/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1211613223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,520.00 | 10/06/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES PL | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.82 | 10/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184244715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 10/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184244717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $311.19 | 10/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184244719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 10/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184244721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,166.08 | 10/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184244723 |
| Principal investigator 1 | PFIZER INC. | $1,128.60 | 09/30/2025 | Non-covered Recipient Entity Hope and Healing CancerService | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228812176 |
| Principal investigator 1 | PFIZER INC. | $25,250.00 | 09/27/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228836103 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 09/25/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202512408 |
| Principal investigator 1 | ABBVIE INC. | $5,240.70 | 09/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202511930 |
| Principal investigator 1 | ABBVIE INC. | $2,200.00 | 09/18/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202511290 |
| Principal investigator 1 | ABBVIE INC. | $13.55 | 09/18/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202511608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.53 | 09/12/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184236606 |
| Principal investigator 1 | ABBVIE INC. | $143.09 | 09/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202510790 |
| Principal investigator 1 | ABBVIE INC. | $10,167.50 | 09/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202510792 |
| Principal investigator 1 | ABBVIE INC. | $137.50 | 09/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202510794 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,148.00 | 09/05/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342768 |
| Principal investigator 1 | BeOne Medicines Ltd. | $22,296.00 | 09/05/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,940.28 | 09/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184235225 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,166.08 | 09/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184235227 |
| Principal investigator 1 | ABBVIE INC. | $3,375.00 | 09/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202507185 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $70.00 | 08/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223284651 |
| Principal investigator 1 | ABBVIE INC. | $8,673.75 | 08/26/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202505845 |
| Principal investigator 1 | PFIZER INC. | $1,706.40 | 08/22/2025 | Non-covered Recipient Entity Hope and Healing CancerService | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228812170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $81.42 | 08/21/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184229771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $645.15 | 08/21/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184229773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,498.82 | 08/14/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,166.08 | 08/14/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,431.47 | 08/14/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228347 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 08/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223284153 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 08/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202503941 |
| Principal investigator 1 | Coherus Oncology, Inc. | $3,700.00 | 08/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | SRF114-101 | No dispute reported | 06/30/2026 | 1235252420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,720.00 | 08/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414404 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,084.80 | 08/01/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223283563 |
| Principal investigator 1 | PFIZER INC. | $6,750.00 | 07/31/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228843490 |
| Principal investigator 1 | ABBVIE INC. | $2,200.00 | 07/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202500302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 07/25/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.82 | 07/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $335.84 | 07/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.00 | 07/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/21/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175414416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93,498.24 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217138 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $83.49 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217140 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $715.53 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217142 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $139.66 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217144 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $560.14 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217146 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,000.00 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.53 | 07/17/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217150 |
| Principal investigator 1 | PFIZER INC. | $24,500.00 | 07/16/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services PLLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228843555 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,645.90 | 07/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223282548 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $70.00 | 07/11/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223282594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,448.24 | 07/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184212901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,466.56 | 07/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184212903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 07/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184212907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 07/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184212909 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $70.00 | 07/02/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223282178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,940.28 | 06/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184209239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.81 | 06/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184209241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $241.50 | 06/19/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184209243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $641.00 | 06/16/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 06/16/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 06/04/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184204045 |
| Principal investigator 1 | ABBVIE INC. | $22,390.00 | 06/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202489453 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,084.80 | 06/02/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICE | Fruquintinib | No dispute reported | 06/30/2026 | 1223280556 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 05/29/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202487091 |
| Principal investigator 1 | Coherus Oncology, Inc. | $24,250.00 | 05/28/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | SRF114-101 | No dispute reported | 06/30/2026 | 1235252405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $936.61 | 05/28/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184198893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,608.56 | 05/28/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184198895 |
| Principal investigator 1 | ABBVIE INC. | $1,437.75 | 05/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202485947 |
| Principal investigator 1 | ABBVIE INC. | $1,437.75 | 05/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202485949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.53 | 05/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184197653 |
| Principal investigator 1 | ABBVIE INC. | $225.45 | 05/15/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202485185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.00 | 05/15/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184194695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $558.90 | 05/15/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184194697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $629.97 | 05/15/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184194699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,160.57 | 05/15/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184194701 |
| Principal investigator 1 | PFIZER INC. | $7,600.00 | 05/14/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services LLC | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228854775 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 05/12/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228822688 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,200.00 | 05/08/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930673 |
| Principal investigator 1 | ABBVIE INC. | $5,240.70 | 05/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202484039 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,520.00 | 05/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414384 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,617.90 | 05/01/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICE | Fruquintinib | No dispute reported | 06/30/2026 | 1223278804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,667.11 | 04/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184189029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.99 | 04/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184189031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,970.76 | 04/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184189033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,764.88 | 04/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184189035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 04/22/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414334 |
| Principal investigator 1 | PFIZER INC. | $27,750.00 | 04/09/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228852040 |
| Principal investigator 1 | ABBVIE INC. | $5,240.70 | 04/08/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202474858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $905.00 | 04/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414389 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 04/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414410 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 04/07/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414435 |
| Principal investigator 1 | Genmab U.S., Inc. | $350.00 | 04/04/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930677 |
| Principal investigator 1 | ABBVIE INC. | $1,437.75 | 04/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202469394 |
| Principal investigator 1 | ABBVIE INC. | $22,200.00 | 04/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202469397 |
| Principal investigator 1 | ABBVIE INC. | $4,313.25 | 03/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202466721 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 03/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202467004 |
| Principal investigator 1 | Genmab U.S., Inc. | $550.00 | 03/27/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930665 |
| Principal investigator 1 | Amgen Inc. | $8,500.00 | 03/25/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LLC | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246642345 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $10,475.67 | 03/18/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181947065 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,774.80 | 03/14/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223276751 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 03/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202463214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,195.00 | 03/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,361.00 | 03/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414344 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,777.00 | 03/10/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414365 |
| Principal investigator 1 | Genmab U.S., Inc. | $263.90 | 03/06/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930637 |
| Principal investigator 1 | Genmab U.S., Inc. | $977.60 | 03/06/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930640 |
| Principal investigator 1 | Genmab U.S., Inc. | $550.00 | 03/06/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930651 |
| Principal investigator 1 | ABBVIE INC. | $15,466.25 | 03/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202455875 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 03/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223276005 |
| Principal investigator 1 | Janssen Research & Development, LLC | $412.00 | 03/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175414350 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 02/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202454421 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,179.42 | 02/13/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930654 |
| Principal investigator 1 | Genmab U.S., Inc. | $550.00 | 02/13/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930662 |
| Principal investigator 1 | Genmab U.S., Inc. | $392.60 | 02/13/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $293.00 | 02/13/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414377 |
| Principal investigator 1 | AstraZeneca UK Limited | $84,418.99 | 02/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185539513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,534.00 | 02/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184152482 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,250.00 | 02/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184152484 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,000.00 | 02/05/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICESLLC LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184152486 |
| Principal investigator 1 | ABBVIE INC. | $21,700.00 | 01/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202441279 |
| Principal investigator 1 | ABBVIE INC. | $21,700.00 | 01/27/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES L | M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202441283 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,700.00 | 01/24/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | Fruquintinib | No dispute reported | 06/30/2026 | 1223274459 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,870.00 | 01/23/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES LL C | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1175414311 |
| Principal investigator 1 | Genmab U.S., Inc. | $8,534.50 | 01/16/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930658 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $2,716.60 | 01/14/2025 | Non-covered Recipient Entity Hope and Healing Cancer Services LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181947063 |
| Principal investigator 1 | Genmab U.S., Inc. | $8,534.50 | 01/09/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930644 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,331.00 | 01/09/2025 | Non-covered Recipient Entity HOPE & HEALING CANCER SERVICES | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235930647 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,389.61 | 01/03/2025 | Non-covered Recipient Entity HOPE AND HEALING CANCER SERVICES | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185539507 |